Invivyd shares are trading higher after the company announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody aimed at preventing symptomatic COVID-19.

Benzinga Newsdesk www.benzinga.com Positive 95.0%

Neg 0% Neu 0% Pos 95%

Comments

No comments yet. Be the first!